Abstract
The relative efficacies of cytotoxic chemotherapy regimens in the treatment of advanced breast cancer are generally assessed by comparing response rates in randomised trials. Treatment attempts to prolong survival but trials rarely demonstrate a statistically significant survival advantage: it has been argued that chemotherapy does not prolong survival. The correlation between response rates and survival has been examined by reviewing 79 comparisons between arms with unequal response rates in 50 published trials of chemotherapy in advanced breast cancer. In 73% of comparisons the group with the higher response rate also demonstrated the longer median survival (P less than 0.001). Weighted linear regression showed a statistically significant relationship between relative response rates and survival (P less than 0.001). The number of patients in a comparison did not influence this relationship.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
A'Hern, R., Ebbs, S. & Baum, M. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 57, 615–618 (1988). https://doi.org/10.1038/bjc.1988.140
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.140
This article is cited by
-
Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
BMC Cancer (2020)
-
Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach
Breast Cancer Research and Treatment (2017)
-
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials
BMC Medical Research Methodology (2011)
-
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
British Journal of Cancer (2005)
-
Management of metastatic breast cancer
World Journal of Surgery (1994)